DAWN Share Price Performance
US$6.88
-6.38 (-48.11%)
73.8% undervalued intrinsic discount
US$26.25
Fair Value
Price US$6.88
AnalystConsensusTarget US$26.25
Fair ValueUS$26.25
Share PriceUS$6.88
73.8% undervalued intrinsic discount
DAWN Community Narratives
AN
Fair Value US$26.25 73.8% undervalued intrinsic discount
Pediatric Oncology Adoption And Pipeline Expansion Will Drive Future Success
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
DAWN Community Fair Values
- US$26.25FV73.8% undervalued intrinsic discount36.05%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative6users have followed this narrative13 days ago author updated this narrative
Recent DAWN News & Updates
No updates
Day One Biopharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.68
- Gross Margin
- 94.96%
- Net Profit Margin
- -42.66%
- Debt/Equity Ratio
- 0%
Day One Biopharmaceuticals, Inc. Competitors
About DAWN
- Founded
- 2018
- Employees
- 181
- CEO
- WebsiteView website
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading